Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B
Abstract
:1. Introduction
2. Results
3. Discussion
- da_lipo_5B:
- fringNplaN4B:
- N_H_2B:
- fsp3Csp2N5B:
- fsp2Osp2C5B:
- fOringC6B:
- fringNC6B:
4. Materials and Methods
4.1. Selection of Dataset
4.2. Calculation of Molecular Descriptors and Objective Feature Selection (OFS)
4.3. Splitting the Dataset into Training and External Sets and Subjective Feature Selection (SFS)
4.4. Building Regression Model and Its Validation
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
SMILES | Simplified molecular-input line-entry system |
GA | Genetic algorithm |
MLR | Multiple linear regression |
QSAR | Quantitative structure−activity relationship |
WHO | World Health Organization |
OLS | Ordinary least squares |
QSARINS | QSAR Insubria |
OECD | Organization for Economic Cooperation and Development |
References
- Du, R.; Huang, C.; Liu, K.; Li, X.; Dong, Z. Targeting AURKA in Cancer: Molecular mechanisms and opportunities for Cancer therapy. Mol. Cancer 2021, 20, 15. [Google Scholar] [CrossRef] [PubMed]
- Garuti, L.; Roberti, M.; Bottegoni, G. Small Molecule Aurora Kinases Inhibitors. Curr. Med. Chem. 2009, 16, 1949–1963. [Google Scholar] [CrossRef] [PubMed]
- Pollard, J.R.; Mortimore, M. Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents. J. Med. Chem. 2009, 52, 2629–2651. [Google Scholar] [CrossRef] [PubMed]
- Jing, X.L.; Chen, S.W. Aurora kinase inhibitors: A patent review (2014–2020). Expert Opin. Ther. Pat. 2021, 31, 625–644. [Google Scholar] [CrossRef] [PubMed]
- Willems, E.; Dedobbeleer, M.; Digregorio, M.; Lombard, A.; Lumapat, P.N.; Rogister, B. The functional diversity of Aurora kinases: A comprehensive review. Cell Div. 2018, 13, 7. [Google Scholar] [CrossRef] [Green Version]
- Borisa, A.C.; Bhatt, H.G. A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. Eur. J. Med. Chem. 2017, 140, 1–19. [Google Scholar] [CrossRef]
- Bavetsias, V.; Linardopoulos, S. Aurora Kinase Inhibitors: Current Status and Outlook. Front. Oncol. 2015, 5, 278. [Google Scholar] [CrossRef] [Green Version]
- Kollareddy, M.; Zheleva, D.; Dzubak, P.; Brahmkshatriya, P.S.; Lepsik, M.; Hajduch, M. Aurora kinase inhibitors: Progress towards the clinic. Investig. New Drugs 2012, 30, 2411–2432. [Google Scholar] [CrossRef] [Green Version]
- Lok, W.; Klein, R.Q.; Saif, M.W. Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 2010, 21, 339–350. [Google Scholar] [CrossRef]
- He, Y.; Fu, W.; Du, L.; Yao, H.; Hua, Z.; Li, J.; Lin, Z. Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti-aspergillus fumigatus dual efficacies in vitro. J. Enzym. Inhib. Med. Chem. 2022, 37, 109–117. [Google Scholar] [CrossRef]
- Keen, N.; Taylor, S. Mitotic drivers—Inhibitors of the Aurora B Kinase. Cancer Metastasis Rev. 2009, 28, 185–195. [Google Scholar] [CrossRef] [Green Version]
- Kong, Y.; Bender, A.; Yan, A. Identification of Novel Aurora Kinase A (AURKA) Inhibitors via Hierarchical Ligand-Based Virtual Screening. J. Chem. Inf. Model. 2018, 58, 36–47. [Google Scholar] [CrossRef]
- Durlacher, C.T.; Li, Z.L.; Chen, X.W.; He, Z.X.; Zhou, S.F. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor. Clin. Exp. Pharmacol. Physiol. 2016, 43, 585–601. [Google Scholar] [CrossRef] [Green Version]
- Imam, S.S.; Gilani, S.J. Computer Aided Drug Design: A Novel Loom to Drug Discovery. Org. Med. Chem. 2017, 1, 1–6. [Google Scholar] [CrossRef]
- Baig, M.H.; Ahmad, K.; Roy, S.; Ashraf, J.M.; Adil, M.; Siddiqui, M.H.; Khan, S.; Kamal, M.A.; Provaznik, I.; Choi, I. Computer Aided Drug Design: Success and Limitations. Curr. Pharm. Des. 2016, 22, 572–581. [Google Scholar] [CrossRef]
- Macalino, S.J.; Gosu, V.; Hong, S.; Choi, S. Role of computer-aided drug design in modern drug discovery. Arch. Pharm. Res. 2015, 38, 1686–1701. [Google Scholar] [CrossRef]
- Gramatica, P. Principles of QSAR Modeling. Int. J. Quant. Struct.-Prop. Relatsh. 2020, 5, 61–97. [Google Scholar] [CrossRef]
- Fujita, T.; Winkler, D.A. Understanding the Roles of the “Two QSARs”. J. Chem. Inf. Model. 2016, 56, 269–274. [Google Scholar] [CrossRef]
- Cherkasov, A.; Muratov, E.N.; Fourches, D.; Varnek, A.; Baskin, I.I.; Cronin, M.; Dearden, J.; Gramatica, P.; Martin, Y.C.; Todeschini, R.; et al. QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 2014, 57, 4977–5010. [Google Scholar] [CrossRef] [Green Version]
- Neaz, M.; Muddassar, M.; Pasha, F.; Cho, S.J. Structural studies of B-type Aurora kinase inhibitors using computational methods. Acta Pharmacol. Sin. 2010, 31, 244–258. [Google Scholar] [CrossRef]
- Lan, P.; Chen, W.N.; Sun, P.H.; Chen, W.M. 3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors. J. Mol. Model. 2011, 17, 1191–1205. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, S.; Ranaghan, K.E.; Woods, C.J.; Mulholland, A.J.; Ul-Haq, Z. Exploration of the structural requirements of Aurora Kinase B inhibitors by a combined QSAR, modelling and molecular simulation approach. Sci. Rep. 2021, 11, 18707. [Google Scholar] [CrossRef] [PubMed]
- Gramatica, P. External Evaluation of QSAR Models, in Addition to Cross-Validation Verification of Predictive Capability on Totally New Chemicals. Mol. Inform. 2014, 33, 311–314. [Google Scholar] [CrossRef] [PubMed]
- Chirico, N.; Gramatica, P. Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection. J. Chem. Inf. Model. 2012, 52, 2044–2058. [Google Scholar] [CrossRef] [PubMed]
- Chirico, N.; Gramatica, P. Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J. Chem. Inf. Model. 2011, 51, 2320–2335. [Google Scholar] [CrossRef]
- Gramatica, P. Principles of QSAR models validation internal and external. QSAR Comb. Sci. 2007, 26, 694–701. [Google Scholar] [CrossRef]
- Gramatica, P. On the development and validation of QSAR models. Methods Mol. Biol. 2013, 930, 499–526. [Google Scholar] [CrossRef]
- Rao, R.B.; Fung, G.; Rosales, R. On the Dangers of Cross-Validation. An Experimental Evaluation. In Proceedings of the 2008 SIAM International Conference on Data Mining (SDM); Society for Industrial and Applied Mathematics: Philadelphia, PA, USA, 2008; pp. 588–596. [Google Scholar] [CrossRef] [Green Version]
- Tropsha, A.; Gramatica, P.; Gombar, V.K. The Importance of Being Earnest Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models. QSAR Comb. Sci. 2003, 22, 69–77. [Google Scholar] [CrossRef]
- Hawkins, D.M.; Basak, S.C.; Mills, D. Assessing model fit by cross-validation. J. Chem. Inf. Comput. Sci. 2003, 43, 579–586. [Google Scholar] [CrossRef]
- Lučić, B.; Batista, J.; Bojović, V.; Lovrić, M.; Sović Kržić, A.; Bešlo, D.; Nadramija, D.; Vikić-Topić, D. Estimation of Random Accuracy and its Use in Validation of Predictive Quality of Classification Models within Predictive Challenges. Croat. Chem. Acta 2019, 92, 379–391. [Google Scholar] [CrossRef] [Green Version]
- Masand, V.H.; Mahajan, D.T.; Nazeruddin, G.M.; Hadda, T.B.; Rastija, V.; Alfeefy, A.M. Effect of information leakage and method of splitting (rational and random) on external predictive ability and behavior of different statistical parameters of QSAR model. Med. Chem. Res. 2014, 24, 1241–1264. [Google Scholar] [CrossRef]
- Kar, S.; Roy, K.; Leszczynski, J. Applicability Domain: A Step Toward Confident Predictions and Decidability for QSAR Modeling. In Computational Toxicology; Humana Press: New York, NY, USA, 2018; pp. 141–169. [Google Scholar] [CrossRef]
- Roy, P.P.; Kovarich, S.; Gramatica, P. QSAR model reproducibility and applicability A case study of rate constants of hydroxyl radical reaction models applied to polybrominated diphenyl ethers and (benzo-)triazoles. J. Comput. Chem. 2011, 32, 2386–2396. [Google Scholar] [CrossRef]
- Sushko, I.; Novotarskyi, S.; Korner, R.; Pandey, A.K.; Cherkasov, A.; Li, J.; Gramatica, P.; Hansen, K.; Schroeter, T.; Muller, K.R.; et al. Applicability domains for classification problems: Benchmarking of distance to models for Ames mutagenicity set. J. Chem. Inf. Model. 2010, 50, 2094–2111. [Google Scholar] [CrossRef]
- Tropsha, A.; Golbraikh, A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr. Pharm. Des. 2007, 13, 3494–3504. [Google Scholar] [CrossRef]
- Masand, V.H.; Rastija, V. PyDescriptor: A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. Chemom. Intell. Lab. Syst. 2017, 169, 12–18. [Google Scholar] [CrossRef]
- Todeschini, R.; Consonni, V. Molecular Descriptors for Chemoinformatics; Wiley-VCH: Weinheim, Germany, 2009. [Google Scholar]
- Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Wiley-VCH: Weinheim, Germany, 2000; Volume 11. [Google Scholar]
- Di, L.; Kerns, E.H. Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization, 2nd ed.; Elsevier/AP: Amsterdam, The Netherlands; Boston, MA, USA, 2016; 560p. [Google Scholar]
- Sessa, F.; Villa, F. Structure of Aurora B-INCENP in complex with barasertib reveals a potential transinhibitory mechanism. Acta Crystallogr. F Struct. Biol. Commun. 2014, 70 Pt 3, 294–298. [Google Scholar] [CrossRef] [Green Version]
- Elkins, J.M.; Santaguida, S.; Musacchio, A.; Knapp, S. Crystal structure of human aurora B in complex with INCENP and VX-680. J. Med. Chem. 2012, 55, 7841–7848. [Google Scholar] [CrossRef]
- Masand, V.H.; Mahajan, D.T.; Gramatica, P.; Barlow, J. Tautomerism and multiple modelling enhance the efficacy of QSAR: Antimalarial activity of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl. Med. Chem. Res. 2014, 23, 4825–4835. [Google Scholar] [CrossRef]
- Masand, V.H.; Mahajan, D.T.; Ben Hadda, T.; Jawarkar, R.D.; Alafeefy, A.M.; Rastija, V.; Ali, M.A. Does tautomerism influence the outcome of QSAR modeling? Med. Chem. Res. 2014, 23, 1742–1757. [Google Scholar] [CrossRef]
- Zaki, M.E.A.; Al-Hussain, S.A.; Bukhari, S.N.A.; Masand, V.H.; Rathore, M.M.; Thakur, S.D.; Patil, V.M. Exploring the Prominent and Concealed Inhibitory Features for Cytoplasmic Isoforms of Hsp90 Using QSAR Analysis. Pharmaceuticals 2022, 15, 303. [Google Scholar] [CrossRef]
- Zaki, M.E.A.; Al-Hussain, S.A.; Al-Mutairi, A.A.; Masand, V.H.; Samad, A.; Jawarkar, R.D. Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures. Pharmaceuticals 2022, 15, 745. [Google Scholar] [CrossRef]
- Fourches, D.; Muratov, E.; Tropsha, A. Trust, but verify: On the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model. 2010, 50, 1189–1204. [Google Scholar] [CrossRef]
- O’Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. J. Cheminform. 2011, 3, 33. [Google Scholar] [CrossRef] [Green Version]
- Stewart, J.J.P. MOPAC: A semiempirical molecular orbital program. J. Comput.-Aided Mol. Des. 1990, 4, 1–103. [Google Scholar] [CrossRef]
- Yap, C.W. PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints. J. Comput. Chem. 2011, 32, 1466–1474. [Google Scholar] [CrossRef]
- Gramatica, P.; Chirico, N.; Papa, E.; Cassani, S.; Kovarich, S. QSARINS: A new software for the development, analysis, and validation of QSAR MLR models. J. Comput. Chem. 2013, 34, 2121–2132. [Google Scholar] [CrossRef]
- Bukhari, S.N.A.; Elsherif, M.A.; Junaid, K.; Ejaz, H.; Alam, P.; Samad, A.; Jawarkar, R.D.; Masand, V.H. Perceiving the Concealed and Unreported Pharmacophoric Features of the 5-Hydroxytryptamine Receptor Using Balanced QSAR Analysis. Pharmaceuticals 2022, 15, 834. [Google Scholar] [CrossRef]
- Consonni, V.; Todeschini, R.; Ballabio, D.; Grisoni, F. On the Misleading Use of Q2F3 for QSAR Model Comparison. Mol. Inf. 2019, 38, e1800029. [Google Scholar] [CrossRef]
- Golbraikh, A.; Muratov, E.; Fourches, D.; Tropsha, A. Data set modelability by QSAR. J. Chem. Inf. Model. 2014, 54, 1–4. [Google Scholar] [CrossRef] [Green Version]
- Martin, T.M.; Harten, P.; Young, D.M.; Muratov, E.N.; Golbraikh, A.; Zhu, H.; Tropsha, A. Does rational selection of training and test sets improve the outcome of QSAR modeling? J. Chem. Inf. Model. 2012, 52, 2570–2578. [Google Scholar] [CrossRef]
- Gramatica, P.; Cassani, S.; Roy, P.P.; Kovarich, S.; Yap, C.W.; Papa, E. QSAR Modeling is not Push a Button and Find a Correlation: A Case Study of Toxicity of (Benzo-)triazoles on Algae. In Molecular Informatics; Wiley Online: Hoboken, NJ, USA, 2012; Volume 31, pp. 817–835. [Google Scholar]
- Huang, J.; Fan, X. Why QSAR fails: An empirical evaluation using conventional computational approach. Mol. Pharm. 2011, 8, 600–608. [Google Scholar] [CrossRef] [PubMed]
Molecular Descriptor | Description |
---|---|
fringNplaN4B | Frequency of occurrence of planer nitrogen atoms exactly at 4 bonds from ring nitrogen atom |
fsp3Csp2N5B | Frequency of occurrence of sp2-hybridized nitrogen atoms exactly at 5 bonds from sp3-hybridized carbon atoms |
N_H_2B | Total number of nitrogen atoms present within 2 bonds from hydrogen atoms |
fsp2Osp2C5B | Frequency of occurrence of sp2-hybridized carbon atoms exactly at 5 bonds from sp2-hybridized oxygen atoms |
da_lipo_5B | Total number of lipophilic atoms present within 5 bonds from H-bond donor cum acceptor atoms |
fOringC6B | Frequency of occurrence of ring carbon atoms exactly at 6 bonds from oxygen atoms |
fringNC6B | Frequency of occurrence of carbon atoms exactly at 6 bonds from ring nitrogen atoms |
TA Form | TB Form | ||||||
---|---|---|---|---|---|---|---|
Residue | Residue Atom | Ligand Atom | Distance | Residue | Residue Atom | Ligand Atom | Distance |
GLU171 | O | N19 | 2.97 | GLU171 | O | N19 | 2.74 |
PHE172 | CA | N20 | 3.47 | PHE172 | CA | N20 | 3.52 |
ALA173 | N | N20 | 2.84 | ALA173 | N | N20 | 2.74 |
ALA173 | O | N14 | 2.93 | ALA173 | O | N14 | 2.91 |
HOH2005 | O | N13 | 3.32 | HOH2005 | O | N30 | 2.80 |
Tautomer with Descriptor Value | H-Bonds Formed with Distance (Å) with Angle (Donor–Hydrogen–Acceptor) (Cut-Off: 5 Å) | List of Receptor Heavy Atoms within 5 Å of N3 atom of Ligand (Residue–Atom–Distance in Å) | List of Receptor Heavy Atoms within 5 Å of N1 Atom of Ligand (Residue–Atom–Distance in Å) |
---|---|---|---|
YJA-T1 fsp3Csp2N5B = 0 N_H_2B = 6 fsp2Osp2C5B = 3 | LYS122 at 1.668 with 159.8°, GLN145 at 2.251 with 142.4, ALA173 at 1.952 with 163.9° | VAL107-CB-4.672, VAL107-CG1-4.351, VAL107-CG2-4.419, LU177-OE2-4.842, LEU223-CG-4.608, LEU223-CD1-3.627, LEU223-CD2-4.406 | LEU99-CD1-4.259, ALA120-CB-4.501, GLU171-C-4.888, GLU171-O-4.058, PHE172-N-4.808, PHE172-CA-3.818, PHE172-C-3.832, PHE172-CB-4.641, PHE172-CG-4.403, PHE172-CD1-3.550, PHE172-CE1-4.156, ALA173-N-2.936, ALA173-CA-3.743, ALA173-C-4.208, ALA173-O-3.930, ALA173-CB-3.623, LEU223-CD1-4.121 |
YJA-T2 fsp3Csp2N5B = 1 N_H_2B = 7 fsp2Osp2C5B = 3 | LYS122 at 2.361 with 157.8°, GLN145 at 2.323 with 115.7°, ALA173 at 1.946 with 174.4°, HOH2108 2.222 with 106.7° | PHE104-CG-4.358, PHE104-CD2-3.203, PHE104-CE2-3.058, PHE104-CZ-4.124, VAL107-CB-4.591, VAL107-CG1-4.413, VAL107-CG2-4.142, LEU223-CD1-4.047, LEU223-CD2-4.948 | LEU99-CD2-3.977, ALA120-CB-4.707, GLU171-C-4.734, GLU171-O-3.872, PHE172-N-4.690, PHE172-CA-3.669, PHE172-C-3.814, PHE172-CB-4.567, PHE172-CG-4.418, PHE172-CD1-3.618, PHE172-CE1-4.265, ALA173-N-2.953, ALA173-CA-3.799, ALA173-C-4.271, ALA173-O-3.915, ALA173-CB-3.635, LEU223-CD1-4.165 |
Mol ID | SMILES | IC50 (nM) | pIC50 (M) |
---|---|---|---|
339 | O=C(Nc1cc(CNc2ncnc3c(C(=O)N)cccc23)ccc1)c1cnc(NC)cc1 | 0.26 | 9.585 |
326 | O=C(Nc1cc(C(Nc2ncnc3c(C(=O)N)cccc23)C)ccc1)c1[nH]nc(C(C)C)c1 | 0.27 | 9.569 |
350 | O=C(Nc1cc(CNc2ncnc3c(C(=O)N)cccc23)ccc1)c1[nH]nc2c1CCCC2 | 0.3 | 9.523 |
316 | O=C(Nc1cc(C(Nc2ncnc3c(C(=O)N)cccc23)C)ccc1)c1cnc(C)cc1 | 0.32 | 9.495 |
383 | O=C(Nc1cc(CNc2ncnc3c(C(=O)N)cccc23)ccc1)c1[nH]nc(C(C)C)c1 | 0.33 | 9.481 |
191 | O=C1OCc2c(C)c(O)c(O)c(O)c12 | 8690 | 5.061 |
506 | O=C(c1nc(Nc2n[nH]c(C)c2)c2c(n1)cccc2)c1ccccc1 | 11,500 | 4.939 |
202 | O=C(C)c1scc(-c2cnc3[nH]c(-c4ccc(OC)cc4)nc3c2)c1 | 12,100 | 4.917 |
427 | O=C(O)c1cnc(Nc2nccc(/C=C\3/C(=O)N(C)/C(=N/c4ccc(CC)cc4)/S/3)c2)cc1 | 12,505.05 | 4.903 |
194 | O(C)c1c(Nc2ncc3c([nH]c(-c4c(C)onc4C)c3)c2)cccc1 | 16,000 | 4.796 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Masand, V.H.; Al-Hussain, S.A.; Rathore, M.M.; Thakur, S.D.; Akasapu, S.; Samad, A.; Al-Mutairi, A.A.; Zaki, M.E.A. Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B. Int. J. Mol. Sci. 2022, 23, 14527. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314527
Masand VH, Al-Hussain SA, Rathore MM, Thakur SD, Akasapu S, Samad A, Al-Mutairi AA, Zaki MEA. Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B. International Journal of Molecular Sciences. 2022; 23(23):14527. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314527
Chicago/Turabian StyleMasand, Vijay H., Sami A. Al-Hussain, Mithilesh M. Rathore, Sumer D. Thakur, Siddhartha Akasapu, Abdul Samad, Aamal A. Al-Mutairi, and Magdi E. A. Zaki. 2022. "Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B" International Journal of Molecular Sciences 23, no. 23: 14527. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314527